The SWAN Impact Network is pleased to announce an investment in Sonnest. Sonnest is transforming cardiac ultrasound. Their Electrast™ is the first electrically sensitive imaging agent for assessing and monitoring the perfusion, structure, and function of the heart, allowing low cost ultrasound procedures to provide information only previously available from much higher cost scans.  Electrast™ is a contrast agent that activates with ultrasound and the heart’s local electric field if the heart tissue is perfused and viable. Sonnest allows Doctors to:

  • Analyze better data, faster. Cardiac perfusion data in point of care setting.
  • Diagnose- No cath lab needed. Most cost-effective diagnosis without harmful radiation.
  • Respond – Triage and treat. Improve patient care and outcomes confidently.